76
|
Adare A, Afanasiev S, Aidala C, Ajitanand NN, Akiba Y, Al-Bataineh H, Alexander J, Al-Jamel A, Aoki K, Aphecetche L, Armendariz R, Aronson SH, Asai J, Atomssa ET, Averbeck R, Awes TC, Azmoun B, Babintsev V, Baksay G, Baksay L, Baldisseri A, Barish KN, Barnes PD, Bassalleck B, Bathe S, Batsouli S, Baublis V, Bauer F, Bazilevsky A, Belikov S, Bennett R, Berdnikov Y, Bickley AA, Bjorndal MT, Boissevain JG, Borel H, Boyle K, Brooks ML, Brown DS, Bucher D, Buesching H, Bumazhnov V, Bunce G, Burward-Hoy JM, Butsyk S, Campbell S, Chai JS, Chang BS, Charvet JL, Chernichenko S, Chiba J, Chi CY, Chiu M, Choi IJ, Chujo T, Chung P, Churyn A, Cianciolo V, Cleven CR, Cobigo Y, Cole BA, Comets MP, Constantin P, Csanád M, Csörgo T, Dahms T, Das K, David G, Deaton MB, Dehmelt K, Delagrange H, Denisov A, d'Enterria D, Deshpande A, Desmond EJ, Dietzsch O, Dion A, Donadelli M, Drachenberg JL, Drapier O, Drees A, Dubey AK, Durum A, Dzhordzhadze V, Efremenko YV, Egdemir J, Ellinghaus F, Emam WS, Enokizono A, En'yo H, Espagnon B, Esumi S, Eyser KO, Fields DE, Finger M, Finger M, Fleuret F, Fokin SL, Forestier B, Fraenkel Z, Frantz JE, Franz A, Frawley AD, Fujiwara K, Fukao Y, Fung SY, Fusayasu T, Gadrat S, Garishvili I, Gastineau F, Germain M, Glenn A, Gong H, Gonin M, Gosset J, Goto Y, Granier de Cassagnac R, Grau N, Greene SV, Grosse Perdekamp M, Gunji T, Gustafsson HA, Hachiya T, Hadj Henni A, Haegemann C, Haggerty JS, Hagiwara MN, Hamagaki H, Han R, Harada H, Hartouni EP, Haruna K, Harvey M, Haslum E, Hasuko K, Hayano R, Heffner M, Hemmick TK, Hester T, Heuser JM, He X, Hiejima H, Hill JC, Hobbs R, Hohlmann M, Holmes M, Holzmann W, Homma K, Hong B, Horaguchi T, Hornback D, Hur MG, Ichihara T, Imai K, Inaba M, Inoue Y, Isenhower D, Isenhower L, Ishihara M, Isobe T, Issah M, Isupov A, Jacak BV, Jia J, Jin J, Jinnouchi O, Johnson BM, Joo KS, Jouan D, Kajihara F, Kametani S, Kamihara N, Kamin J, Kaneta M, Kang JH, Kano H, Kanou H, Kawagishi T, Kawall D, Kazantsev AV, Kelly S, Khanzadeev A, Kikuchi J, Kim DH, Kim DJ, Kim E, Kim YS, Kinney E, Kiss A, Kistenev E, Kiyomichi A, Klay J, Klein-Boesing C, Kochenda L, Kochetkov V, Komkov B, Konno M, Kotchetkov D, Kozlov A, Král A, Kravitz A, Kroon PJ, Kubart J, Kunde GJ, Kurihara N, Kurita K, Kweon MJ, Kwon Y, Kyle GS, Lacey R, Lai YS, Lajoie JG, Lebedev A, Le Bornec Y, Leckey S, Lee DM, Lee MK, Lee T, Leitch MJ, Leite MAL, Lenzi B, Lim H, Liska T, Litvinenko A, Liu MX, Li X, Li XH, Love B, Lynch D, Maguire CF, Makdisi YI, Malakhov A, Malik MD, Manko VI, Mao Y, Masek L, Masui H, Matathias F, McCain MC, McCumber M, McGaughey PL, Miake Y, Mikes P, Miki K, Miller TE, Milov A, Mioduszewski S, Mishra GC, Mishra M, Mitchell JT, Mitrovski M, Morreale A, Morrison DP, Moss JM, Moukhanova TV, Mukhopadhyay D, Murata J, Nagamiya S, Nagata Y, Nagle JL, Naglis M, Nakagawa I, Nakamiya Y, Nakamura T, Nakano K, Newby J, Nguyen M, Norman BE, Nyanin AS, Nystrand J, O'Brien E, Oda SX, Ogilvie CA, Ohnishi H, Ojha ID, Okada H, Okada K, Oka M, Omiwade OO, Oskarsson A, Otterlund I, Ouchida M, Ozawa K, Pak R, Pal D, Palounek APT, Pantuev V, Papavassiliou V, Park J, Park WJ, Pate SF, Pei H, Peng JC, Pereira H, Peresedov V, Peressounko DY, Pinkenburg C, Pisani RP, Purschke ML, Purwar AK, Qu H, Rak J, Rakotozafindrabe A, Ravinovich I, Read KF, Rembeczki S, Reuter M, Reygers K, Riabov V, Riabov Y, Roche G, Romana A, Rosati M, Rosendahl SSE, Rosnet P, Rukoyatkin P, Rykov VL, Ryu SS, Sahlmueller B, Saito N, Sakaguchi T, Sakai S, Sakata H, Samsonov V, Sato HD, Sato S, Sawada S, Seele J, Seidl R, Semenov V, Seto R, Sharma D, Shea TK, Shein I, Shevel A, Shibata TA, Shigaki K, Shimomura M, Shohjoh T, Shoji K, Sickles A, Silva CL, Silvermyr D, Silvestre C, Sim KS, Singh CP, Singh V, Skutnik S, Slunecka M, Smith WC, Soldatov A, Soltz RA, Sondheim WE, Sorensen SP, Sourikova IV, Staley F, Stankus PW, Stenlund E, Stepanov M, Ster A, Stoll SP, Sugitate T, Suire C, Sullivan JP, Sziklai J, Tabaru T, Takagi S, Takagui EM, Taketani A, Tanaka KH, Tanaka Y, Tanida K, Tannenbaum MJ, Taranenko A, Tarján P, Thomas TL, Togawa M, Toia A, Tojo J, Tomásek L, Torii H, Towell RS, Tram VN, Tserruya I, Tsuchimoto Y, Tuli SK, Tydesjö H, Tyurin N, Vale C, Valle H, van Hecke HW, Velkovska J, Vertesi R, Vinogradov AA, Virius M, Vrba V, Vznuzdaev E, Wagner M, Walker D, Wang XR, Watanabe Y, Wessels J, White SN, Willis N, Winter D, Woody CL, Wysocki M, Xie W, Yamaguchi YL, Yanovich A, Yasin Z, Ying J, Yokkaichi S, Young GR, Younus I, Yushmanov IE, Zajc WA, Zaudtke O, Zhang C, Zhou S, Zimányi J, Zolin L. Scaling properties of azimuthal anisotropy in Au+Au and Cu+Cu Collisions at sqrt[s NN]=200 GeV. PHYSICAL REVIEW LETTERS 2007; 98:162301. [PMID: 17501413 DOI: 10.1103/physrevlett.98.162301] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/16/2006] [Indexed: 05/15/2023]
Abstract
Differential measurements of elliptic flow (v2) for Au+Au and Cu+Cu collisions at sqrt[sNN]=200 GeV are used to test and validate predictions from perfect fluid hydrodynamics for scaling of v2 with eccentricity, system size, and transverse kinetic energy (KE T). For KE T identical with mT-m up to approximately 1 GeV the scaling is compatible with hydrodynamic expansion of a thermalized fluid. For large values of KE T mesons and baryons scale separately. Quark number scaling reveals a universal scaling of v2 for both mesons and baryons over the full KE T range for Au+Au. For Au+Au and Cu+Cu the scaling is more pronounced in terms of KE T, rather than transverse momentum.
Collapse
|
77
|
Luczyński W, Iłendo E, Kovalchuk O, Krawczuk-Rybak M, Malinowska I, Kołtan A, Szczepański T, Wysocka J, Jaworowski R, Olejnik I, Chyczewski L, Matysiak M, Wysocki M, Sońta-Jakimczyk D, Wieczorek M. Acute lymphoblastic leukaemia cells express CCR7 but not higher amounts of IL-10 after CD40 ligation. Scandinavian Journal of Clinical and Laboratory Investigation 2007; 66:695-703. [PMID: 17101562 DOI: 10.1080/00365510600931098] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
OBJECTIVE Production of cytokines that support T-cell activation and proliferation and migration to lymph nodes is one of the most important terms of cancer vaccine development. In previous studies we and others used CD40 ligation to obtain higher expression of co-stimulatory and adhesion molecules on leukaemic cells from children with acute lymphoblastic leukaemia (ALL). This time we assess the cytokine and chemokine gene expression profile in CD40-stimulated ALL cells. MATERIAL AND METHODS Malignant cells from 25 children with BCP-ALL were stimulated (or not) with huCD40LT and rIL-4 for 96 h. Eleven different molecule, cytokine and chemokine mRNAs levels (CCR7, IL-23, TGF-beta-IP, IFN-gamma, IL-10, CD1a, CD40, CD54, CD80, CD83, CD86) were determined using the real-time PCR technique with TaqMan chemistry using ready-to-use low-density arrays for gene expression by Applied Biosystems. RESULTS 1) Increases in mRNA levels for CD40, CD54 and CD80 after CD40L and IL-4 stimulation were observed, 2) CCR7 mRNA expression was higher after CD40 ligation than before the culture (p = 0.002), 3) IL-10 mRNA expression was higher after the culture with medium than before the culture (p = 0.01). CONCLUSIONS The results show that leukaemia-derived dendritic cells obtained with CD40 ligation express CCR7 - chemokine is involved in migration to lymph nodes and does not produce higher amounts of IL-10, a potent immunosuppressive cytokine. Our preclinical findings could be used in the design of immunotherapy trials for the treatment of children with ALL.
Collapse
|
78
|
Adare A, Afanasiev S, Aidala C, Ajitanand NN, Akiba Y, Al-Bataineh H, Alexander J, Aoki K, Aphecetche L, Armendariz R, Aronson SH, Asai J, Atomssa ET, Averbeck R, Awes TC, Azmoun B, Babintsev V, Baksay G, Baksay L, Baldisseri A, Barish KN, Barnes PD, Bassalleck B, Bathe S, Batsouli S, Baublis V, Bazilevsky A, Belikov S, Bennett R, Berdnikov Y, Bickley AA, Boissevain JG, Borel H, Boyle K, Brooks ML, Buesching H, Bumazhnov V, Bunce G, Butsyk S, Campbell S, Chang BS, Charvet JL, Chernichenko S, Chiba J, Chi CY, Chiu M, Choi IJ, Chujo T, Chung P, Churyn A, Cianciolo V, Cleven CR, Cole BA, Comets MP, Constantin P, Csanád M, Csörgo T, Dahms T, Das K, David G, Deaton MB, Dehmelt K, Delagrange H, Denisov A, d'Enterria D, Deshpande A, Desmond EJ, Dietzsch O, Dion A, Donadelli M, Drapier O, Drees A, Dubey AK, Durum A, Dzhordzhadze V, Efremenko YV, Egdemir J, Ellinghaus F, Emam WS, Enokizono A, En'yo H, Esumi S, Eyser KO, Fields DE, Finger M, Fleuret F, Fokin SL, Fraenkel Z, Franz A, Frantz J, Frawley AD, Fujiwara K, Fukao Y, Fusayasu T, Gadrat S, Garishvili I, Glenn A, Gong H, Gonin M, Gosset J, Goto Y, Granier de Cassagnac R, Grau N, Greene SV, Grosse Perdekamp M, Gunji T, Gustafsson HA, Hachiya T, Henni AH, Haegemann C, Haggerty JS, Hamagaki H, Han R, Harada H, Hartouni EP, Haruna K, Haslum E, Hayano R, Heffner M, Hemmick TK, Hester T, He X, Hiejima H, Hill JC, Hobbs R, Hohlmann M, Holzmann W, Homma K, Hong B, Horaguchi T, Hornback D, Ichihara T, Imai K, Inaba M, Inoue Y, Isenhower D, Isenhower L, Ishihara M, Isobe T, Issah M, Isupov A, Jacak BV, Jia J, Jin J, Jinnouchi O, Johnson BM, Joo KS, Jouan D, Kajihara F, Kametani S, Kamihara N, Kamin J, Kaneta M, Kang JH, Kanou H, Kano H, Kawall D, Kazantsev AV, Khanzadeev A, Kikuchi J, Kim DH, Kim DJ, Kim E, Kinney E, Kiss A, Kistenev E, Kiyomichi A, Klay J, Klein-Boesing C, Kochenda L, Kochetkov V, Komkov B, Konno M, Kotchetkov D, Kozlov A, Král A, Kravitz A, Kubart J, Kunde GJ, Kurihara N, Kurita K, Kweon MJ, Kwon Y, Kyle GS, Lacey R, Lai YS, Lajoie JG, Lebedev A, Lee DM, Lee MK, Lee T, Leitch MJ, Leite MAL, Lenzi B, Liska T, Litvinenko A, Liu MX, Li X, Love B, Lynch D, Maguire CF, Makdisi YI, Malakhov A, Malik MD, Manko VI, Mao Y, Masek L, Masui H, Matathias F, McCumber M, McGaughey PL, Miake Y, Mikes P, Miki K, Miller TE, Milov A, Mioduszewski S, Mishra M, Mitchell JT, Mitrovski M, Morreale A, Morrison DP, Moukhanova TV, Mukhopadhyay D, Murata J, Nagamiya S, Nagata Y, Nagle JL, Naglis M, Nakagawa I, Nakamiya Y, Nakamura T, Nakano K, Newby J, Nguyen M, Norman BE, Nyanin AS, O'Brien E, Oda SX, Ogilvie CA, Ohnishi H, Okada H, Okada K, Oka M, Omiwade OO, Oskarsson A, Ouchida M, Ozawa K, Pak R, Pal D, Palounek APT, Pantuev V, Papavassiliou V, Park J, Park WJ, Pate SF, Pei H, Peng JC, Pereira H, Peresedov V, Peressounko DY, Pinkenburg C, Purschke ML, Purwar AK, Qu H, Rak J, Rakotozafindrabe A, Ravinovich I, Read KF, Rembeczki S, Reuter M, Reygers K, Riabov V, Riabov Y, Roche G, Romana A, Rosati M, Rosendahl SSE, Rosnet P, Rukoyatkin P, Rykov VL, Sahlmueller B, Saito N, Sakaguchi T, Sakai S, Sakata H, Samsonov V, Sato S, Sawada S, Seele J, Seidl R, Semenov V, Seto R, Sharma D, Shein I, Shevel A, Shibata TA, Shigaki K, Shimomura M, Shoji K, Sickles A, Silva CL, Silvermyr D, Silvestre C, Sim KS, Singh CP, Singh V, Skutnik S, Slunecka M, Soldatov A, Soltz RA, Sondheim WE, Sorensen SP, Sourikova IV, Staley F, Stankus PW, Stenlund E, Stepanov M, Ster A, Stoll SP, Sugitate T, Suire C, Sziklai J, Tabaru T, Takagi S, Takagui EM, Taketani A, Tanaka Y, Tanida K, Tannenbaum MJ, Taranenko A, Tarján P, Thomas TL, Togawa M, Toia A, Tojo J, Tomásek L, Torii H, Towell RS, Tram VN, Tserruya I, Tsuchimoto Y, Vale C, Valle H, van Hecke HW, Velkovska J, Vertesi R, Vinogradov AA, Virius M, Vrba V, Vznuzdaev E, Wagner M, Walker D, Wang XR, Watanabe Y, Wessels J, White SN, Winter D, Woody CL, Wysocki M, Xie W, Yamaguchi Y, Yanovich A, Yasin Z, Ying J, Yokkaichi S, Young GR, Younus I, Yushmanov IE, Zajc WA, Zaudtke O, Zhang C, Zhou S, Zimányi J, Zolin L. Measurement of high-pT single electrons from heavy-flavor decays in p + p collisions at square root of s = 200 GeV. PHYSICAL REVIEW LETTERS 2006; 97:252002. [PMID: 17280343 DOI: 10.1103/physrevlett.97.252002] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/06/2006] [Indexed: 05/13/2023]
Abstract
The momentum distribution of electrons from decays of heavy flavor (charm and bottom) for midrapidity absolute value of y < 0.35 in p + p collisions at square root of s = 200 GeV has been measured by the PHENIX experiment at the BNL Relativistic Heavy Ion Collider over the transverse momentum range 0.3 < pT < 9 GeV/c. Two independent methods have been used to determine the heavy-flavor yields, and the results are in good agreement with each other. A fixed-order-plus-next-to-leading-log perturbative QCD calculation agrees with the data within the theoretical and experimental uncertainties, with the data/theory ratio of 1.71+/-0.02stat+/-0.18sys for 0.3 < pT < 9 GeV/c. The total charm production cross section at this energy has also been deduced to be sigma cc = 567+/-57stat+/-193sys microb.
Collapse
|
79
|
Dluzniewska A, Balwierz W, Armata J, Balcerska A, Chybicka A, Kowalczyk J, Matysiak M, Ochocka M, Radwanska U, Rokicka-Milewska R, Sonta-Jakimczyk D, Wachowiak J, Wysocki M. Twenty years of Polish experience with three consecutive protocols for treatment of childhood acute myelogenous leukemia. Leukemia 2006; 19:2117-24. [PMID: 16107894 DOI: 10.1038/sj.leu.2403892] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Until 1983, results of treatment of acute myelogenous leukemia (AML) in Poland with different regimens were very poor. In 1983, the Polish Pediatric Leukemia/Lymphoma Study Group introduced a unified treatment protocol--a modified version of BFM-83 protocol. This led to an increase in the curability of AML from 15% to approximately 32%. In 1994, a modification was made: the high-risk patients (>5% blasts in bone marrow on day 15 of therapy and all M5 cases) received two additional cycles with intermediate-dose cytarabine (ID-ARAC). This led to a nonsignificant improvement in the 5-year event-free survival (EFS) rate from 32 to 36%. A new treatment protocol employing idarubicin in place of daunorubicin was introduced in 1998 and produced better initial responses, increase in the number of patients attaining remission after induction therapy and proportional increase of standard-risk patients. The probability of 5-year EFS (pEFS) for the whole group of patients increased from 36 to 47%. In standard- and high-risk groups, the 5-year pEFS was 62 and 33%, respectively. The probability of 5-year disease-free survival was 58% in the whole group, and there were no differences between risk groups. Unsatisfactory treatment results in children classified into the high-risk group are principally due to the low remission rate.
Collapse
|
80
|
Styczynski J, Koltan A, Wysocki M. Resistance to glucocorticoids in childhood acute lymphoblastic leukemia: impact of relationship between ex vivo sensitivity and in vivo concentration on risk factor analysis. Neoplasma 2006; 53:168-73. [PMID: 16575474] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/08/2023]
Abstract
Resistance to glucocorticoids remains one of the main obstacles in therapy of childhood acute lymphoblastic leukemia (ALL). The aim of the study was the analysis of relationship between ex vivo drug resistance of prednisolone and dexamethasone and exposure to these drugs in childhood ALL, with respect to risk factor analysis. Ex vivo resistance to both glucocorticoids was compared to maximum drug concentration achievable in body fluids, calculated in mathematical model. Drug resistance to vincristine and L-asparaginase, expression of multidrug resistance and apoptosis proteins was also determined. Concentration of both glucocorticoids in extracellular fluid was higher than drug resistance in the following groups of patients: in initial ALL patients, in patients staying in remission during follow-up, and in prednisolone good responders. Factors significant by multivariate analysis were early bone marrow response by day 15 and concentration of prednisolone higher than ex vivo prednisolone resistance. For initial ALL patients with determined response to initial prednisolone monotherapy, factors significant by univariate analysis were early bone marrow response, and exposure to glucocorticoids higher than ex vivo resistance to these drugs. No factor was significant by multivariate analysis in this group. Risk factor analysis showed that concentration of prednisolone and dexamethasone higher than respective ex vivo drug resistance, is a strongest prognostic factor in childhood ALL.
Collapse
|
81
|
Adler SS, Afanasiev S, Aidala C, Ajitanand NN, Akiba Y, Al-Jamel A, Alexander J, Amirikas R, Aoki K, Aphecetche L, Armendariz R, Aronson SH, Averbeck R, Awes TC, Azmoun B, Azmoun R, Babintsev V, Baldisseri A, Barish KN, Barnes PD, Bassalleck B, Bathe S, Batsouli S, Baublis V, Bauer F, Bazilevsky A, Belikov S, Bennett R, Berdnikov Y, Bhagavatula S, Bjorndal MT, Boissevain JG, Borel H, Borenstein S, Boyle K, Brooks ML, Brown DS, Bruner N, Bucher D, Buesching H, Bumazhnov V, Bunce G, Burward-Hoy JM, Butsyk S, Camard X, Campbell S, Chai JS, Chand P, Chang WC, Chernichenko S, Chi CY, Chiba J, Chiu M, Choi IJ, Choi J, Choudhury RK, Chujo T, Cianciolo V, Cleven CR, Cobigo Y, Cole BA, Comets MP, Constantin P, Csanád M, Csörgo T, d'Enterria D, Dahms T, Das K, David G, Delagrange H, Denisov A, Deshpande A, Desmond EJ, Devismes A, Dietzsch O, Dion A, Drachenberg JL, Drapier O, Drees A, Drees KA, Dubey AK, du Rietz R, Durum A, Dutta D, Dzhordzhadze V, Efremenko YV, Egdemir J, El Chenawi K, Enokizono A, En'yo H, Espagnon B, Esumi S, Ewell L, Fields DE, Fleuret F, Fokin SL, Forestier B, Fox BD, Fraenkel Z, Frantz JE, Franz A, Frawley AD, Fukao Y, Fung SY, Gadrat S, Garpman S, Gastineau F, Germain M, Ghosh TK, Glenn A, Gogiberidze G, Gonin M, Gosset J, Goto Y, Granier de Cassagnac R, Grau N, Greene SV, Perdekamp MG, Gunji T, Guryn W, Gustafsson HA, Hachiya T, Henni AH, Haggerty JS, Hagiwara MN, Hamagaki H, Hansen AG, Harada H, Hartouni EP, Haruna K, Harvey M, Haslum E, Hasuko K, Hayano R, Hayashi N, He X, Heffner M, Hemmick TK, Heuser JM, Hibino M, Hiejima H, Hill JC, Hobbs R, Holmes M, Holzmann W, Homma K, Hong B, Hoover A, Horaguchi T, Hur HM, Ichihara T, Ikonnikov VV, Imai K, Inaba M, Isenhower D, Isenhower L, Ishihara M, Isobe T, Issah M, Isupov A, Jacak BV, Jang WY, Jeong Y, Jia J, Jin J, Jinnouchi O, Johnson BM, Johnson SC, Joo KS, Jouan D, Kajihara F, Kametani S, Kamihara N, Kaneta M, Kang JH, Kapoor SS, Katou K, Kawagishi T, Kazantsev AV, Kelly S, Khachaturov B, Khanzadeev A, Kikuchi J, Kim DH, Kim DJ, Kim DW, Kim E, Kim GB, Kim HJ, Kim YS, Kinney E, Kinnison WW, Kiss A, Kistenev E, Kiyomichi A, Kiyoyama K, Klein-Boesing C, Kobayashi H, Kochenda L, Kochetkov V, Koehler D, Kohama T, Komkov B, Konno M, Kopytine M, Kotchetkov D, Kozlov A, Kroon PJ, Kuberg CH, Kunde GJ, Kurihara N, Kurita K, Kuroki Y, Kweon MJ, Kwon Y, Kyle GS, Lacey R, Ladygin V, Lajoie JG, Le Bornec Y, Lebedev A, Leckey S, Lee DM, Lee MK, Lee S, Leitch MJ, Leite MAL, Li XH, Lim H, Litvinenko A, Liu MX, Liu Y, Maguire CF, Makdisi YI, Malakhov A, Malik MD, Manko VI, Mao Y, Martinez G, Marx MD, Masui H, Matathias F, Matsumoto T, McCain MC, McGaughey PL, Melnikov E, Messer F, Miake Y, Milan J, Miller TE, Milov A, Mioduszewski S, Mischke RE, Mishra GC, Mitchell JT, Mohanty AK, Morrison DP, Moss JM, Moukhanova TV, Mühlbacher F, Mukhopadhyay D, Muniruzzaman M, Murata J, Nagamiya S, Nagata Y, Nagle JL, Naglis M, Nakamura T, Nandi BK, Nara M, Newby J, Nguyen M, Nilsson P, Norman B, Nyanin AS, Nystrand J, O'Brien E, Ogilvie CA, Ohnishi H, Ojha ID, Okada H, Okada K, Omiwade OO, Ono M, Onuchin V, Oskarsson A, Otterlund I, Oyama K, Ozawa K, Pal D, Palounek APT, Pantuev V, Papavassiliou V, Park J, Park WJ, Parmar A, Pate SF, Pei H, Peitzmann T, Peng JC, Pereira H, Peresedov V, Peressounko DY, Pinkenburg C, Pisani RP, Plasil F, Purschke ML, Purwar AK, Qu H, Rak J, Ravinovich I, Read KF, Reuter M, Reygers K, Riabov V, Riabov Y, Roche G, Romana A, Rosati M, Rosendahl SSE, Rosnet P, Rukoyatkin P, Rykov VL, Ryu SS, Sadler ME, Sahlmueller B, Saito N, Sakaguchi T, Sakai M, Sakai S, Samsonov V, Sanfratello L, Santo R, Sato HD, Sato S, Sawada S, Schutz Y, Semenov V, Seto R, Sharma D, Shaw MR, Shea TK, Shein I, Shibata TA, Shigaki K, Shiina T, Shimomura M, Shohjoh T, Shoji K, Sickles A, Silva CL, Silvermyr D, Sim KS, Simon-Gillo J, Singh CP, Singh V, Sivertz M, Skutnik S, Smith WC, Soldatov A, Soltz RA, Sondheim WE, Sorensen SP, Sourikova IV, Staley F, Stankus PW, Stenlund E, Stepanov M, Ster A, Stoll SP, Sugitate T, Suire C, Sullivan JP, Sziklai J, Tabaru T, Takagi S, Takagui EM, Taketani A, Tamai M, Tanaka KH, Tanaka Y, Tanida K, Tannenbaum MJ, Taranenko A, Tarján P, Tepe JD, Thomas TL, Togawa M, Tojo J, Torii H, Towell RS, Tram VN, Tserruya I, Tsuchimoto Y, Tsuruoka H, Tuli SK, Tydesjö H, Tyurin N, Valle H, van Hecke HW, Velkovska J, Velkovsky M, Vertesi R, Veszprémi V, Villatte L, Vinogradov AA, Volkov MA, Vznuzdaev E, Wagner M, Wang XR, Watanabe Y, Wessels J, White SN, Willis N, Winter D, Wohn FK, Woody CL, Wysocki M, Xie W, Yang Y, Yanovich A, Yokkaichi S, Young GR, Younus I, Yushmanov IE, Zajc WA, Zaudkte O, Zhang C, Zhou S, Zhou SJ, Zimányi J, Zolin L. Saturation of azimuthal anisotropy in Au + Au collisions at (square root)s(NN) = 62-200 GeV. PHYSICAL REVIEW LETTERS 2005; 94:232302. [PMID: 16090463 DOI: 10.1103/physrevlett.94.232302] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/19/2004] [Indexed: 05/03/2023]
Abstract
New measurements are presented for charged hadron azimuthal correlations at midrapidity in Au+Au collisions at (square root)s(NN) = 62.4 and 200 GeV. They are compared to earlier measurements obtained at (square root)s(NN) = 130 GeV and in Pb + Pb collisions at (square root)s(NN) = 17.2 GeV. Sizeable anisotropies are observed with centrality and transverse momentum (pT) dependence characteristic of elliptic flow (upsilon2). For a broad range of centralities, the observed magnitudes and trends of the differential anisotropy, upsilon2(pT), change very little over the collision energy range (square root)s(NN) = 62-200 GeV, indicating saturation of the excitation function for upsilon2 at these energies. Such a saturation may be indicative of the dominance of a very soft equation of state for (square root)s(NN) approximately 60-200 GeV.
Collapse
|
82
|
Koltan S, Koltan A, Wysocki M, Debski R, Styczynski J. Anti-HBs profiles in children treated for neoplastic disease who had been vaccinated against hepatitis B postnatally or as infants. J Hosp Infect 2005; 60:73-7. [PMID: 15823661 DOI: 10.1016/j.jhin.2004.09.041] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2004] [Accepted: 09/27/2004] [Indexed: 11/16/2022]
Abstract
Children with cancer are a risk group for hepatitis B virus (HBV) infection. In Poland, the initiation of a national HBV vaccination programme in neonates and infants in 1995 has contributed to the prevention of HBV infection in children treated for neoplastic diseases. The objective of this study was to analyse the anti-HBs pattern and occurrence of HBV infections in children with cancer who had been vaccinated during infancy. The study included 96 children divided into three groups: Group A, children who had received a full vaccination course with an initial level of anti-HBs >/=100 IU/L; Group B, children who had received a full vaccination course with anti-HBs <100 IU/L, for whom an additional dose of vaccine was administered; and Group C, children who had further immunoprophylaxis because they did not complete the vaccination course before cancer diagnosis. A protective level of anti-HBs after the full vaccination programme was found in 80.5% of children after three months, 74.2% after six months, 61.5% after 12 months and 78.6% after 18 months. Among children who produced antibodies, a slow decrease in the level of anti-HBs was observed. It was still protective during follow-up in Group A, but occasionally fell below 100 IU/L in Group B. In Group C, five of 11 subjects had a protective level of anti-HBs throughout follow-up. Of 28 children who showed the presence of HBsAg during follow-up, 23 eradicated the virus. In children with cancer vaccinated against HBV according to the vaccination schedule, the immune response maintains a protective level of anti-HBs in more than 60% of cases, despite immunosuppression.
Collapse
|
83
|
Styczynski J, Wysocki M, Debski R, Czyzewski K, Balwierz W, Juraszewska E, Matysiak M, Malinowska I, Stanczak E, Sońta-Jakimczyk D, Szczepanski T, Wachowiak J, Konatkowska B, Balcerska A, Ploszynska A, Kowalczyk J, Stefaniak J, Badowska W, Wieczorek M, Olejnik I, Krawczuk-Rybak M, Kuzmicz M. In vitro sensitivity of leukemic cells to nucleoside derivatives in childhood acute leukemias: good activity in leukemic relapses. Neoplasma 2005; 52:74-8. [PMID: 15739031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/01/2023]
Abstract
Nucleoside analogues such as fludarabine and cladribine are used in therapy of indolent lymphomas and leukemias in adults, while cytarabine is used mainly in protocols for acute leukemias. Mechanisms of their activity is based on inhibition of enzymes involved in DNA, RNA and protein synthesis. The objective of the study was the analysis of in vitro cellular drug sensitivity in childhood acute lymphoblastic (ALL) and myeloid (AML) leukemia. Isolated leukemic cells obtained from 264 patients, including 152 initial ALL, 45 relapsed ALL, 54 initial AML and 13 relapsed AML were tested for cytotoxicity for fludarabine, cladribine, and cytarabine by the MTT assay. Drug concentration lethal to 50% of tested cells was regarded as a value of drug resistance. Three tested nucleoside analogues showed highest cytotoxicity against initial ALL samples. Samples of relapsed ALL and initial AML were more resistant than ALL de novo ones. Unexpectedly, no differences were observed between initial and relapsed AML samples for all tested drugs, what suggests that nucleoside analogues are active drugs in relapsed AML, which is commonly regarded as a resistant disease. All tested drugs presented significant cross-resistance in each of analyzed subgroups. In summary, tested nucleoside analogues presented relatively good activity against childhood leukemias at relapse stage.
Collapse
|
84
|
Müntefering H, Wysocki M, Rastorguev E, Gerein V. [Placenta in gestational hypertension]. DER PATHOLOGE 2004; 25:262-8. [PMID: 15060725 DOI: 10.1007/s00292-004-0687-4] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
At an incidence of 3.2-4% world-wide, pregnancy-induced hypertension (PIH) is the most common disease of pregnancy. Since this holds a risk, not only for the mother, but also for the child, the placenta should undergo pathological-anatomical examination in every case. Pathomorphological findings can be described in the feto-maternal border zone as well as in the fetal placenta. These are not, however, specific, nor do they offer diagnostic proof. Pathomorphological findings in the feto-maternal border zone: defective invasion of the extravillous cytotrophoblast, hyperplastic arterio-/arteriolopathy, acute atherosclerosis, and fibrinoid necrosis of endothelium. Disorders of the fetal part of placenta: infarctions/fibrin deposits, obliterative angiopathy, stromal fibrosis/fibrinoid degeneration, syncytiotrophoblastic nodes (Tenney-Parker-phenomenon), and disturbances of maturation of the villi. There is a general lack of correlation between the seriousness of the disease and the morphology. The only exception in this respect are the findings in the vessels both of the placental bed and of the chronic villi. These show a high correlation with doppler sonographic findings.
Collapse
|
85
|
Mlosek K, Wysocki M, Sieluzycka JG, Jakubowski W, Pienkowska ES. The value of three-dimensional (3D) ultrasound examination in the assessment of small breast tumours. Breast Cancer Res 2004. [PMCID: PMC3300435 DOI: 10.1186/bcr894] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2023] Open
|
86
|
Kazanowska B, Reich A, Reich M, Balcerska A, Balwierz W, Bodalski J, Dłuzniewska A, Drozyńska E, Katski K, Kijowski J, Kowalczyk J, Kurylak A, Matysiak M, Mikołajewska A, Peregut-Pogorzelski J, Sopyło B, Stencel D, Szewczyk B, Wachowiak J, Wieczorek M, Wysocki M, Chybicka A. Remaining problems and controversies in the management of childhood head and neck soft tissue sarcomas: Retrospective (national) Multicenter Study of the Polish Pediatric Solid Tumors Group. Pediatr Hematol Oncol 2004; 21:349-62. [PMID: 15205098 DOI: 10.1080/08880010490440491] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
Soft tissue sarcomas in children are a heterogeneous group of malignant diseases. Among these, tumors localized in the head and neck region are especially difficult to treat. While multidisciplinary care has dramatically improved the prognosis of sarcoma patients, their treatment remains uncertain because of demand on radical surgical resection of the tumor. Achieving cure without deforming or mutilating the child remains the primary goal of treatment. This study is the multicenter (nationwide, 11 Polish centers) retrospective analysis of the treatment results in children having soft tissue sarcoma in the head and neck region during the previous decade (from 1991 to 2001). Late effects of the treatment are documented in long-term survivals. Eighty-five children from 1 to 212 months of age were included. Different multimodal treatment protocols were utilized (CWS-91, SIOP-MMT-91, and CWS-96). The median observation time was 25 months. Data on long-term effects were collected in 34 long-term survivals. Complete remission was achieved in 68 (80%) patients. Primary treatment failure occurred in 13 (15.3%) patients, all of whom succumbed in disease progression. Relapse occurred in 21 (30.9%) patients primarily achieving complete remission. Second primary neoplasm occurred in 3 children. The estimated 5-year event-free survival and the 5-year total survival rates for the whole group are 0.38 and 0.55, respectively. The main late effect documented in long-term survivals were cosmetic defects in 12 (35.3%) and visual field deficit or blindness in 8 (26.5%). Despite substantial improvement of the prognosis of pediatric soft tissue sarcomas, the multimodal treatment of head and neck region tumors remains controversial. Improved long-term outcome and focusing on psychosocial difficulties raise the important and difficult problem of functional results and cosmesis. Tumors localized in the orbit carry an excellent prognosis. However, the main late sequela is vision impairment and cosmetic defect due to the therapy given many years earlier. Two other tumor localizations--the parameningeal and nonparameningeal ones--still have bad prognosis. The observations made in this study confirm that main prognostic factors are the size of the primary tumor and the tumor stage. The worst prognosis remains invasive tumor (T2-stage) with a size over 5 cm. Individually adjusted multimodal therapy, which imperatively needs to be radical, though not mutilating, might minimize the late effects. Psychosocial problems in long-term survivors need to be focused on at the national level and better support must be provided in the future, involving a team of different medical and paramedical profiles.
Collapse
|
87
|
Skoczen S, Klus K, Armata J, Kowalczyk J, Wisniewska-Slusarz H, Kolecki P, Derwich K, Matysiak M, Krauze A, Rokicka-Milewska R, Pawelec K, Boguslawska-Jaworska J, Juszczak K, Pisarek J, Sońta-Jakimczyk D, Tomaszewska R, Łuszczynska A, Wysocki M, Styczyński J. [High risk acute lymphoblastic leukaemia in children. Preliminary report after introducing a new version of New York (1997) protocol adjusted to the age of the patients. Report of the Polish Paediatric Leukaemia/Lymphoma Study Group]. MEDYCYNA WIEKU ROZWOJOWEGO 2003; 4:23-32. [PMID: 12021459] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/25/2023]
Abstract
The paper presents the experience of the Polish Paediatric Leukaemia/Lymphoma Study Group in the treatment of high-risk acute lymphoblastic leukaemia in children using a new version of the New York (1997-1999). Protocol with treatment intensity adjusted according to the age of the patients. From April 1997 to December 1999 a group of 49 children with leukocytosis ranging from 50 900/mm3 to 580 000/mm3 (median 122 000/mm3) and 6 children with leukocytosis below 50 000/mm3 and poor response to steroids were treated with this protocol. Children below 10 years (43 patients) were treated according to the previous protocol, children above 10 years (12 patients) were treated with intensified protocol (high doses of ARA-C in consolidation and intermediate doses of Mtx in maintenance). Induction was identical for all patients. Complete remission was achieved in 92.6% patients. There were 2 relapses. Six children died - 3 without remission, 2 due to a relapse, 1 due to treatment complications. The current opinions concerning classification of HRG-ALL and treatment possibilities in this group of children are discussed.
Collapse
|
88
|
Chybicka A, Kałwak K, Bogusławska-Jaworska J, Turkiewicz D, Armata J, Balcerska A, Bubała H, Boruczkowski D, Cwiklińska M, Hicke A, Kaczmarek-Kanold M, Kolecki P, Kowalczyk J, Krauze A, Matysiak M, Płoszyńska A, Rokicka-Milewska R, Sońta-Jakimczyk D, Sikorska-Fic B, Staszak-Kowalska R, Tomaszewska R, Wiśniewska-Slusarz H, Wachowiak J, Wysocki M. [Results of treatment of children with chronic myelogenous leukaemia (CML) obtained by the Polish Paediatric Leukaemia/Lymphoma Study Group]. MEDYCYNA WIEKU ROZWOJOWEGO 2003; 4:49-55. [PMID: 12021462] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/25/2023]
Abstract
Retrospective analysis of 102 children with CML from 9 paediatric centres in Poland has been performed. A total number of 102 children: 58 boys and 44 girls aged 1-17 years (median 9.4 years old) with CML, treated in the period 1975-1999 were included in the study. Forty eight of 102 (47.1 %) children were treated with cytostatic drugs without IFN alpha: busulfan, hydroxyurea, 6-mercaptopurine or etoposide (VP-16). Fifty four of 102 (52.9%) patients were treated with interferon alpha (IFN alpha) after cytoreductive pretreatment. Thirty out of 102 (29.4%) patients underwent stem cell transplantation (SCT): 24 - matched related donor allo-BMT, 2 - matched unrelated donor allo-BMT, 1 - partially matched related donor T-cell depleted allo-PBPCT, 1 - syngeneic allo-BMT and 2 - autologous PBPCT. Overall survival analysis revealed that 46 of the 102 (45.1%) children remained alive: 5/35 (14.3%) children treated with cytostatics alone, 22/37 (59.5%) children treated with IFN alpha and 19/30 (63.3%) children treated with SCT. Among SCT survivors there are 10/17 (58.8%) children treated with IFN alpha prior to SCT and 9/13 (69.2%) children treated with cytostatics alone prior to SCT. The probability of 5-year survival is 0.51 in the group treated with SCT (median follow-up 58 months); 0.43 in the group treated with IFN alpha (median follow-up 53 months) and 0.23 in the group treated with cytostatics (median follow-up 31 months). Our data show, that BMT is the treatment of choice in CML in children. IFN alpha could be successfully applied as an alternative treatment for those, who do not have a suitable donor for allogeneic SCT. Better outcome in post BMT children, who were not treated with IFN alpha prior to SCT requires confirmation by studies on larger groups of patients. However, it seems to be justified to stop IFN alpha therapy at least 3 months before SCT. The main reason for unsuccessful treatment outcome in patients with CML in Poland remains the still insufficient access to MUD-BMT.
Collapse
|
89
|
Wróbel G, Dobaczewski G, Kazanowska B, Bogusławska-Jaworska J, Balwierz W, Balcerska A, Bubała H, Dluzniewska A, Kołecki P, Kowalczyk J, Kurylak A, Maciejka-Kapuscinska L, Matysiak M, Rokicka-Milewska R, Sońta-Jakimczyk D, Sopyło B, Stefaniak MJ, Stefańska K, Stańczak E, Wysocki M. [Adverse reactions associated with the use of L-asparaginase during therapy of patients with nB non-Hodgkin's lymphoma. Report of the Polish Paediatric LeuKaemia/Lymphoma Study Group]. MEDYCYNA WIEKU ROZWOJOWEGO 2003; 4:67-72. [PMID: 12021464] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/25/2023]
Abstract
The aim of the study was to determine the side effects of asparaginase administration during treatment protocol for childhood non-Hodgkin's lymphoma (NHL). Drug adverse reactions occurred in 20/66 of patients (30,3%) treated in 9 centres in Poland between 1993 and 1998. The most common side effects were coagulation disturbances in 12/66 of the children (18,2%), which occurred due to reduced production of important coagulation factors. Six patients (9,1%) developed impairment of liver function (9,1%). Drug toxicity caused the modifications of treatment protocol in 12/66 (18,2%) of patients, mainly in the induction phase; 3 children died due to relapse of disease.
Collapse
|
90
|
Chybicka A, Wójcik D, Pietras W, Bogusławska-Jaworska J, Kolecki P, Balcerska A, Balwierz W, Bubała H, Eliasinska A, Kowalczyk J, Jackowska T, Klus K, Krenke K, Kurylak A, Malinowska I, Matysiak M, Stefańska K, Stefaniak MJ, Rokicka-Milewska R, Wiśniewska-Slusarz H, Sońta-Jakimczyk D, Wysocki M. [Results of the treatment of myelodysplastic syndrome (MDS)obtained by the Polish Paediatric Leukaemia /Lymphoma Study Group]. MEDYCYNA WIEKU ROZWOJOWEGO 2003; 4:85-90. [PMID: 12021466] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/25/2023]
Abstract
Sixty children with MDS treated in six centres of the Polish Paediatric Leukaemia/Lymphoma Study Group in the period 1975-1999 were included in the study. In 20 children RAEB-T, in 13 RA, in 21 RAEB and in 6 CMML were diagnosed. Our own and literature data showed that BMT is the best therapy for children with MDS. We need a new comprehensive protocol for the diagnosis and treatment of children with MDS in Poland.
Collapse
|
91
|
Chybicka A, Bogusławska-Jaworska J, Rosińska B, Wecławek-Tompol J, Armata J, Balcerska A, Balwierz W, Bubala H, Drabko K, Eliasinska A, Kedziora M, Sońta-Jakimczyk D, Sopylo B, Kołecki P, Kowalczyk J, Matysiak M, Rokicka-Milewska R, Stefaniak MJ, Stańczak E, Stencel D, Wysocki M, Płoszyńska A. [G-CSF and GM-CSF in treatment of neutropaenia after chemotherapy in children with neoplasms]. MEDYCYNA WIEKU ROZWOJOWEGO 2003; 4:121-9. [PMID: 12021471] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/25/2023]
Abstract
A total number of 608 cycles of G-CSF and/or GM-CSF was applied in 280 patients aged from 6 months to 20 years during neutropaenia associated with chemotherapy of children's neoplasms (NHL-124, NBL-42, RMS-36, Nephroblastoma-18, Osteosarcoma-17, Ewing's Sarcoma-14, Hepatoblastoma-6, Neurofibrosarcoma-6, PNET-5, Medulloblastoma-3, Fibrohistiocytoma-3, Angiosarcoma-2, other - 4). G-CSF - Neupogen (Filgastrim, Hoffman La Roche - 492 cycles) and GM-CSF - Leucomax (Molgramostim, Shering Plough - 116 cycles) were administered 5 mg/kg/day s.c. Forty one children with malignancies (NHL -21 cases, solid tumours -17) treated before cytokines were in use served as a control group. Our study demonstrated that G-CSF and GM-CSF therapy, gives a shorter period of neutropaenia, reduction of the number of febrile days, decreased frequency of infection and shortened its duration.
Collapse
|
92
|
Kazanowska B, Wróbel G, Jaworski W, Bogusławska-Jaworska J, Jeleń M, Armata J, Balcerska A, Bubala H, Dluzniewska A, Kołecki P, Kowalczyk J, Kurylak A, Matysiak M, Ploszyńska A, Rokicka-Milewska R, Sońta-Jakimczyk D, Sopylo B, Stańczak E, Stefaniak MJ, Stefańska K, Wysocki M, Gacka M. [Abdominal presentation of B-cell non-Hodgkin's lymphoma (B-NHL) - surgical treatment and its results. Report of the Polish Paediatric Leukaemia/Lymphoma Study Group]. MEDYCYNA WIEKU ROZWOJOWEGO 2003; 4:57-66. [PMID: 12021463] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/25/2023]
Abstract
The aim of this study was to analyse the effect of LMB-89 protocol and surgical procedure at initial laparotomy on the outcome in children with abdominal B-cell NHL. The initial surgery intervention was: complete resection (20% pts), subtotal resection (20%), partial resection (4%), biopsy (36%). Postoperative complications occurred in 5 children. Complete recovery (CR) was achieved in 92% pts. There were 4% non responder patients. Two patients died before CR evaluation (tumour lysis syndrome; bleeding and multi organ failure after initial surgery). One patient died in CCR from sepsis probably influenced by the previous local operation. 10.8% patients relapsed. The estimate EFS for all patients with AB-NHL is 81%, 85% for stage III and 73% for stage IV. Major surgery in advanced stages is not recommended since it delays chemotherapy and fails to improve overall survival.
Collapse
|
93
|
Chybicka A, Bogusławska-Jaworska J, Gorczyńska E, Armata J, Balcerska A, Balwierz W, Bubala H, Filiks-Litwin B, Kołecki P, Kowalczyk J, Łukowska K, Matysiak M, Rokicka-Milewska R, Rola-Kurc E, Stencel D, Sonta-Jakimczyk D, Strojny W, Wachowiak J, Wieczorek M, Wysocki M, Zelenay E. [Preliminary results of BFM 96 protocol in treatment of childhood ALL relapse in the experience of the Polish Paediatric Leukaemia /Lymphoma Study Group]. MEDYCYNA WIEKU ROZWOJOWEGO 2003; 4:43-8. [PMID: 12021461] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/25/2023]
Abstract
Between 1998 and 1999, 36 children aged from 3 months to 18 years (10 girls and 26 boys) with first relapse of acute lymphoblastic leukaemia were included in the study. The children were treated according to the BFM 96 relapse protocol. There were 24 cases with early (including 9 children with very early) and 12 cases with late relapse ( BM-20, local extra BM-6, combined 10). The overall second complete remission (CR) rate was 83,33%. The probability of overall EFS after 2 years was 73,3%. The results obtained with BFM 96 chemotherapy in children with first late relapse are acceptable. For children with early relapses, megachemotherapy with BMT in second remission should be used.
Collapse
|
94
|
Pielesz A, Freeman H, Wesełucha-Birczyńska A, Wysocki M, Włochowicz A. Assessing secondary structure of a dyed wool fibre by means of FTIR and FTR spectroscopies. J Mol Struct 2003. [DOI: 10.1016/s0022-2860(03)00210-2] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
95
|
Styczyński J, Wysocki M, Balwierz W, Rokicka-Milewska R, Matysiak M, Balcerska A, Kowalczyk A, Wachowiak J, Sońta-Jakimczyk D, Chybicka A. In vitro comparative antileukemic activity of various glucocorticoids in childhood acute leukemia. Neoplasma 2002; 49:178-83. [PMID: 12098004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/25/2023]
Abstract
Resistance to glucocorticoids is nowadays one of the strongest adverse risk factors in the treatment of childhood acute lymphoblastic leukemia (ALL). Differential in vitro antileukemic activity of various glucocorticoids and their cross-resistance pattern in childhood acute lymphoblastic and myeloblastic leukemia was determined by means of the MTT assay in 49 successfully tested samples of childhood acute leukemia. The equivalent antileukemic concentrations of respective drugs against lymphoblasts in de novo ALL samples were: 35 microM of hydrocortisone; 8 microM of prednisolone; 1.6 microM of methylprednisolone; 0.47 microM of dexamethasone and 0.23 microM of betamethasone. In comparison to initial ALL samples, the group of relapsed ALL was more resistant to: prednisolone (38-fold, p=0.004), dexamethasone (>32-fold, p=0.004), methylprednisolone (37-fold, p=0.039), betamethasone (38-fold, p=0.018) and hydrocortisone (33-fold, p=0.030). The group of acute myeloid leukemia (AML) samples were resistant to: prednisolone (>83-fold, p<0.001), dexamethasone (>32-fold, p<0.004), methylprednisolone (>65-fold, p=0.003), betamethasone (>66-fold, p=0.004) and hydrocortisone (61-fold, p=0.007), when compared to ALL at presentation. A significant cross-resistance between all used glucocorticoids as well as between glucocorticoids and other tested anti-leukemic drugs was found. In some individual cases in vitro glucocorticoid cross-resistance was less pronounced and relatively good antileukemic activity of betamethasone was observed.
Collapse
|
96
|
Styczynski J, Koltan A, Haus O, Wysocki M. Differential chemosensitivity in a child with congenital relapsing acute lymphoblastic leukemia. Pediatr Hematol Oncol 2002; 19:355-60. [PMID: 12078867 DOI: 10.1080/08880010290057372] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
Abstract
Described is a case of a boy with congenital acute lymphoblastic leukemia (ALL) with pre-pre-B-ALL immunophenotype, presenting as diarrhea, organomegaly, hyperleucocytosis of 1434 G/L, and tumor lysis syndrome. The lymphoblasts showed low proliferative activity and high in vitro drug sensitivity measured by the MTT assay. An excellent response to therapy was observed, but relapse ocurred 3 months later. On relapse, blasts showed extremely high drug resistance, high expression of P-glycoprotein, and high proliferative activity. The response to therapy was again positive, but a second relapse occurred in 1 month. The MTT assay indicated increasing drug resistance to all drugs. Cytogenetic analysis revealed deletion in 11q23 locus. This unfavorable case shows complex biology and differential drug resistance in congenital leukemia.
Collapse
|
97
|
Styczynski J, Wysocki M, Balwierz W, Kowalczyk JR. Dexrazoxane has no impact on sensitivity of childhood leukemic blasts to daunorubicin. Leukemia 2002; 16:820-5. [PMID: 11986942 DOI: 10.1038/sj.leu.2402474] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2001] [Accepted: 12/19/2001] [Indexed: 11/09/2022]
Abstract
Dexrazoxane (DEX) prevents the formation of free radical, lipid peroxidation and cardiotoxicity caused by anthracyclines. Due to a concern about its possible interference with anthracyclin cytotoxicity, the in vitro effect of DEX on daunorubicin (DNR) cytotoxicity, cell cycle and induction of apoptosis by annexin-V was investigated. The sensitivity to DEX, DNR and their combination was tested by the MTT assay in human promyelocytic leukemia HL-60, the erythroid blast crisis CML K562 cell lines and in 45 children with ALL and AML. Cell cycle analysis and annexin-V expression were performed by flow cytometry. It has been observed that DEX itself weakly, but significantly caused cytotoxicity in both cell lines and in patient samples, especially in initial ALL samples. DEX sensitized K562 and HL60, but not patient samples, to cytotoxicity of DNR. The percentage of necrotic/apoptotic cells, as detected in cell cycle analysis and annexin V staining, was higher after exposure to DEX +/- DNR, when compared to respective samples not treated with DEX, in both cell lines but not in patient samples. Expression of annexin V induced by DEX in both cell lines was enlarged, regardless of the presence of DNR. This difference was not observed in patient samples, however, the number of cells expressing annexin V was higher after exposure to DEX +/- DNR in comparison to respective samples not treated with DEX. In conclusion, it seems that DEX possibly has no impact on the sensitivity of childhood leukemic blasts to DNR, however, has weak cytotoxic properties itself.
Collapse
|
98
|
Szymanowski J, Dudek P, Ratajski J, Wysocki M. Correlations among prostatic-specific antigen, Gleason score, staging and grading in patients after radical prostatectomy. BJU Int 2002; 89:612-3. [PMID: 11942975 DOI: 10.1046/j.1464-410x.2002.02691.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
OBJECTIVES To evaluate the correlation between Gleason grade, T stage, tumour grade and preoperative prostate-specific antigen (PSA) level (< or > 20 ng/mL) in patients after radical prostatectomy (RP). PATIENTS AND METHODS The serum total PSA level was measured 3 months before surgery in 87 patients who then underwent RP between 1994 and 2000; the tumour specimens were staged and graded. RESULTS There were 57 (66%) patients with a PSA level of < 20 ng/mL; in this group only four (7%) patients had a Gleason grade of > 7 and eight (14%) had G3 tumours. Thirty (34%) patients had a PSA level of > 20 ng/mL; in this group only two (7%) patients had a Gleason grade of > 7 and 26 (87%) had G1 and G2 tumours. CONCLUSIONS These results confirm our previous observations that the PSA level cannot be use as the only factor to indicate RP in patients with prostate cancer, but further evaluation on more patients is needed.
Collapse
|
99
|
Wysocki M, Jerzak M. [The role of antiphospholipid antibodies in placental immunopathology]. POSTEP HIG MED DOSW 2002; 55:643-53. [PMID: 11795200] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/23/2023] Open
Abstract
The review highlights recent studies investigating the impact of antiphospholipid antibodies (aPS) on placental tissue destruction. These data suggest that aPS may influence pregnancy outcome. Possible mechanisms of aPS action are analysed.
Collapse
|
100
|
Styczynski J, Wysocki M, Koltan S, Kurylak A. Epidemiologic aspects and preventive strategy of hepatitis B and C viral infections in children with cancer. Pediatr Infect Dis J 2001; 20:1042-9. [PMID: 11734709 DOI: 10.1097/00006454-200111000-00008] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
AIMS We present the efficacy of a strategy to control infections with hepatitis B (HBV) and C viruses (HCV) in children with cancer and assessment of risk for their relatives and health care personnel. A total of 1242 people entered the study, including 558 children with cancer, 193 relatives of infected children, 302 health care workers and 189 controls. METHODS To stop dual HBV and HCV nosocomial infection in the oncology department, a preventive strategy was introduced. It involved immunoprophylaxis against HBV, screening blood donors for HCV infection, intensification of nonspecific prophylaxis, an educational program and estimation of risk for relatives of infected children and health care personnel. RESULTS Retrospective analysis showed that the prevalence of HBV and HCV infections in children with cancer was 74 of 119 (62.2%) and 50 of 92 (54.3%), respectively, with the highest rate among patients with leukemia. Inferior anticancer therapeutic response were obtained in infected children. Specific anti-HBV immunoprophylaxis introduced simultaneously with anticancer therapy resulted in protection of 160 of 168 (95.2%) children in the first 4 years, when 62.9% of patients receiving therapy developed protective antibodies. Screening of blood donors and intensification of nonspecific prophylaxis reduced HCV prevalence to 2.8% during the most recent 1.5 years. Genotype analysis showed that the risk of HCV infection was 0.5% for relatives of infected children. The risk for health care personnel was 0 in the oncology ward and 1.9% in the other departments, and it reached 0.53% in control group. CONCLUSIONS The preventive strategy of viral hepatitis in children with cancer, including passive-active HBV immunoprophylaxis from the beginning of chemotherapy and intensive nonspecific prophylactic measures is effective. With this strategy the risk of intrafamily and occupational infection is low.
Collapse
|